NephCure Kidney International® Names Joshua Tarnoff as Chief Executive Officer
Published: Mar 05, 2018
KING OF PRUSSIA, Pa., March 5, 2018 /PRNewswire-USNewswire/ -- The Board of Directors of NephCure Kidney International today announced that Joshua M. Tarnoff has been named the organization's Chief Executive Officer after an extensive nationwide search. Mr. Tarnoff is the founder of Complexa Inc. and served as its Chief Executive Officer and President for 7 years. Mr. Tarnoff has also held executive positions at JDP Therapeutics, Inc. and Viropharma Inc. Mr. Tarnoff brings over 25 years of pharmaceutical and biotechnology experience to NephCure, spanning from large established companies to leading multiple early-stage start-ups. Mr. Tarnoff holds a Bachelor of Arts degree in biology from LaSalle University, in Philadelphia, PA.
Mr. Tarnoff is excited to move from the corporate pharmaceutical world to a patient advocacy group. He notes, "It's the right time to use my knowledge and experience to directly help patients with Nephrotic Syndrome and FSGS. I'm looking forward to working with the NephCure staff, Board, pharmaceutical partners and most importantly, the patient community, to bring treatments to the market for this debilitating and chronic kidney disease."
Dr. Irv Smokler, NephCure's Board President and founder stated, "Josh's experience and passion for helping others will be a great asset to our organization. We look forward to Josh's leadership and innovation as we approach our 20th year of helping FSGS patients."
NephCure's 17-year history of funding basic science research has moved the field towards pursuing clinical research, with multiple pharmaceutical companies launching trials over the next few years. NephCure is focused on partnering with trial sponsors, educating patients around clinical trial participation and engaging a "trial-ready" community to ensure these trials are successfully recruited and completed. Only by effectively filling and completing these trials can new treatments be brought to the patient community.
Mr. Tarnoff's extensive experience in the drug development industry coupled with NephCure staff's expertise in engaging patients and clinicians is a winning combination for getting therapies in the hands of the patients who need them.
NephCure is always looking for volunteers who are interested in raising awareness and funds in the fight against Nephrotic Syndrome and FSGS. Additional information about NephCure can be found at www.NephCure.org